ScPharmaceuticals Inc - Anticipates Topline Data in Q3 2024, Followed by a Supplemental New Drug Application (Snda) by Year-End 2024, IF Successful
SCPharmaceuticals Inc-預計2024年第三季度的頭號數據,如果成功,將在2024年底之前發佈補充新藥申請(Snda)
ScPharmaceuticals Inc - Anticipates Topline Data in Q3 2024, Followed by a Supplemental New Drug Application (Snda) by Year-End 2024, IF Successful
SCPharmaceuticals Inc-預計2024年第三季度的頭號數據,如果成功,將在2024年底之前發佈補充新藥申請(Snda)
使用瀏覽器的分享功能,分享給你的好友吧